|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Demedts IK, Vermaelen KY and van Meerbeeck
JP: Treatment of extensive-stage small cell lung carcinoma: Current
status and future prospects. Eur Respir J. 35:202–215. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kalemkerian GP: Small Cell Lung Cancer.
Semin Respir Crit Care Med. 37:783–796. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kalemkerian GP and Schneider BJ: Advances
in small cell lung cancer. Hematol Oncol Clin North Am. 31:143–156.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dayen C, Debieuvre D, Molinier O, Raffy O,
Paganin F, Virally J, Larive S, Desurmont-Salasc B, Perrichon M,
Martin F, et al: New insights into stage and prognosis in small
cell lung cancer: An analysis of 968 cases. J Thorac Dis.
9:5101–5111. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen J, Lan T, Hou J, Zhang J, An Y, Tie
L, Pan Y, Liu J and Li X: Atorvastatin sensitizes human non-small
cell lung carcinomas to carboplatin via suppression of AKT
activation and upregulation of TIMP-1. Int J Biochem Cell Biol.
44:759–769. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu JC, Yang TY, Hsu YP, Hao WR, Kao PF,
Sung LC, Chen CC and Wu SY: Statins dose-dependently exert a
chemopreventive effect against lung cancer in COPD patients: A
population-based cohort study. Oncotarget. 7:59618–59629.
2016.PubMed/NCBI
|
|
10
|
Chuang MC, Yang YH, Tsai YH, Hsieh MJ, Lin
YC, Lin CK, Chen PC and Yang TM: Survival benefit associated with
metformin use in inoperable non-small cell lung cancer patients
with diabetes: A population-based retrospective cohort study. PLoS
One. 13:e01911292018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gupta G, de Jesus Andreoli Pinto T,
Chellappan DK, Mishra A, Malipeddi H and Dua K: A clinical update
on metformin and lung cancer in diabetic patients. Panminerva Med.
60:70–75, Epub ahead of print. 2018.PubMed/NCBI
|
|
12
|
Lee YG, Lee E, Kim I, Lee KW, Kim TM, Lee
SH, Kim DW and Heo DS: Cisplatin-based chemotherapy is a strong
risk factor for thromboembolic events in small-cell lung cancer.
Cancer Res Treat. 47:670–675. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seng S, Liu Z, Chiu SK, Proverbs-Singh T,
Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, et al: Risk
of venous thromboembolism in patients with cancer treated with
Cisplatin: A systematic review and meta-analysis. J Clin Oncol.
30:4416–4426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Di Nisio M, Porreca E, Candeloro M, De
Tursi M, Russi I and Rutjes AW: Primary prophylaxis for venous
thromboembolism in ambulatory cancer patients receiving
chemotherapy. Cochrane Database Syst Rev.
12:CD0085002016.PubMed/NCBI
|
|
15
|
Liu ZL, Wang Q, Wang M, Wang B and Huang
LN: Low molecular weight heparin in treating patients with lung
cancer received chemotherapy: A meta-analysis. J Cancer Res Ther.
14:S437–S443. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ek L, Gezelius E, Bergman B, Bendahl PO,
Anderson H, Sundberg J, Wallberg M, Falkmer U, Verma S and Belting
M; Swedish Lung Cancer Study Group (SLUSG), . Randomized phase III
trial of low-molecular-weight heparin enoxaparin in addition to
standard treatment in small-cell lung cancer: The RASTEN trial. Ann
Oncol. 29:398–404. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mehta HJ, Patel V and Sadikot RT: Curcumin
and lung cancer-a review. Target Oncol. 9:295–310. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mahran RI, Hagras MM, Sun D and Brenner
DE: Bringing curcumin to the clinic in cancer prevention: A review
of strategies to enhance bioavailability and efficacy. AAPS J.
19:54–81. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Milhoub M, Pichette A, Sylla B, Gauthier C
and Legault J: Bidesmosidic betulin saponin bearing
L-rhamnopyranoside moieties induces apoptosis and inhibition of
lung cancer cells growth in vitro and in vivo. PLoS One. 13(3):
e01933862018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cháirez-Ramírez MH, Moreno-Jiménez MR,
González-Laredo RF, Gallegos-Infante JA and Rocha-Guzmán NE:
Lupane-type triterpenes and their anti-cancer activities against
most common malignant tumors: A review. EXCLI J. 15:758–771.
2016.PubMed/NCBI
|
|
21
|
Pyo JS, Roh SH, Kim DK, Lee JG, Lee YY,
Hong SS, Kwon SW and Park JH: Anti-cancer effect of Betulin on a
human lung cancer cell line: A pharmacoproteomic approach using 2 D
SDS PAGE coupled with nano-HPLC tandem Mass Spectrometry. Planta
Med. 75:127–131. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suzuki-Yamamoto T, Tanaka S, Tsukayama I,
Takafuji M, Hanada T, Arakawa T, Kawakami Y, Kimoto M and Takahashi
Y: Dioscorea japonica extract down-regulates prostaglandin E2
synthetic pathway and induces apoptosis in lung cancer cells. J
Clin Biochem Nutr. 55:162–167. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou J, Joplin DG, Cross JV and Templeton
DJ: Sulforaphane inhibits prostaglandin E2 synthesis by suppressing
microsomal prostaglandin E synthase 1. PLoS One. 7:e497442012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Parikh PM, Vaid A, Advani SH, Digumarti R,
Madhavan J, Nag S, Bapna A, Sekhon JS, Patil S, Ismail PM, et al:
Randomized, double-blind, placebo-controlled phase II study of
single-agent oral talactoferrin in patients with locally advanced
or metastatic non-small-cell lung cancer that progressed after
chemotherapy. J Clin Oncol. 29:4129–4136. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee IC and Choi BY: Withaferin-A-a natural
anticancer agent with pleitropic mechanisms of action. Int J Mol
Sci. 17:2902016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Senthilnathan P, Padmavathi R, Magesh V
and Sakthisekaran D: Chemotherapeutic efficacy of paclitaxel in
combination with Withania somnifera on benzo(a)pyrene-induced
experimental lung cancer. Cancer Sci. 97:658–664. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Choudhary MI, Hussain S, Yousuf S, Dar A,
Mudassar and Atta-ur-Rahman: Chlorinated and diepoxy withanolides
from Withania somnifera and their cytotoxic effects against human
lung cancer cell line. Phytochemistry. 71:2205–2209. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu X, Chen L, Liang T, Tian XD, Liu Y and
Zhang T: Withaferin A induces mitochondrial-dependent apoptosis in
non-small cell lung cancer cells via generation of reactive oxygen
species. J BUON. 22:244–250. 2017.PubMed/NCBI
|
|
29
|
Khan N, Afaq F, Kweon MH, Kim K and
Mukhtar H: Oral consumption of pomegranate fruit extract inhibits
growth and progression of primary lung tumors in mice. Cancer Res.
67:3475–3482. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rahmani AH, Alsahli MA and Almatroodi SA:
Potential antitumor effects of pomegranates and its ingredients.
Pharmacogn Rev. 11:136–140. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao X, Liu X and Su L: Parthenolide
induces apoptosis via TNFRSF10B and PMAIP1 pathways in human lung
cancer cells. J Exp Clin Cancer Res. 33:32014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kajla P, Sharma A and Sood DR: Flaxseed-a
potential functional food source. J Food Sci Technol. 52:1857–1871.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pietrofesa R, Turowski J, Tyagi S, Dukes
F, Arguiri E, Busch TM, Gallagher-Colombo SM, Solomides CC, Cengel
KA and Christofidou-Solomidou M: Radiation mitigating properties of
the lignan component in flaxseed. BMC Cancer. 13:1792013.
View Article : Google Scholar : PubMed/NCBI
|
